Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

McKesson
Medtronic
Merck
McKinsey
Harvard Business School
Dow

Last Updated: November 20, 2019

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 022285

See Plans and Pricing

« Back to Dashboard

NDA 022285 describes KEPPRA XR, which is a drug marketed by Ucb Inc and is included in one NDA. It is available from three suppliers. There is one patent protecting this drug and one Paragraph IV challenge. Additional details are available on the KEPPRA XR profile page.

The generic ingredient in KEPPRA XR is levetiracetam. There are thirty-five drug master file entries for this compound. Eighty-three suppliers are listed for this compound. Additional details are available on the levetiracetam profile page.
Summary for 022285
Tradename:KEPPRA XR
Applicant:Ucb Inc
Ingredient:levetiracetam
Patents:1
Formulation / Manufacturing:see details
Pharmacology for NDA: 022285
Suppliers and Packaging for NDA: 022285
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
KEPPRA XR levetiracetam TABLET, EXTENDED RELEASE;ORAL 022285 NDA UCB, Inc. 50474-598 50474-598-66 60 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE, PLASTIC (50474-598-66)
KEPPRA XR levetiracetam TABLET, EXTENDED RELEASE;ORAL 022285 NDA UCB, Inc. 50474-599 50474-599-66 60 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE, PLASTIC (50474-599-66)
Paragraph IV (Patent) Challenges for 022285
Tradename Dosage Ingredient NDA Submissiondate
KEPPRA XR TABLET, EXTENDED RELEASE;ORAL levetiracetam 022285 2011-01-07

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET, EXTENDED RELEASE;ORALStrength500MG
Approval Date:Sep 12, 2008TE:ABRLD:Yes
Patent:  Start TrialPatent Expiration:Sep 17, 2028Product Flag?YSubstance Flag?Delist Request?

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:TABLET, EXTENDED RELEASE;ORALStrength750MG
Approval Date:Feb 12, 2009TE:ABRLD:Yes
Patent:  Start TrialPatent Expiration:Sep 17, 2028Product Flag?YSubstance Flag?Delist Request?

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Express Scripts
McKesson
McKinsey
Merck
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.